Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled, dose-finding, Phase 2 study of its investigational single-dose sublingual sufentanil NanoTab for acute pain, ARX-04, successfully met its primary endpoint.  Results demonstrated that patients receiving 30 mcg sufentanil NanoTab doses, administered by a healthcare professional, no more frequently than once per hour, had significantly greater pain reduction as measured by Summed Pain Intensity Difference to baseline during the 12-hour study period (SPID-12) than placebo-treated patients (p=0.003).  Adverse events reported in the study were generally mild-to-moderate in nature, with two serious adverse events of post-surgical infection reported, both of which were determined by the investigator to be unrelated to study drug.  Two patients dropped out of the study due to adverse events, one patient's discontinuation considered unrelated to study drug, and the other considered probably related to study drug, both in the 30 mcg-treated group.

"The goal of this program, to find an effective sublingual sufentanil dose that could be administered less frequently by a healthcare professional than our patient-administered ARX-01 product candidate, has been met", said Dr. Pamela Palmer , Chief Medical Officer, AcelRx Pharmaceuticals.  "There is a need for a non-invasive, rapid-onset strong analgesic to provide short-term treatment of pain for the wounded soldier on the battlefield, the trauma victim at the site of a road-traffic accident, the migraine patient in the emergency room, or in g
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... announces that a new market research report is ... Optoelectronics Industry http://www.reportlinker.com/p087331/Global-Optoelectronics-Industry.html ... for Optoelectronics in Millions of US$ by the ... Optical Components. Major segments analyzed under the Optical ...
... Inc. (Pink Sheets: SNDY ) is pleased ... meeting held September 28, 2010 near Solos, headquarters in ... Amanda Segersten and Fred Schiemann were re-elected to serve ... shareholders meeting. The shareholders also approved the motion to ...
Cached Medicine Technology:Reportlinker Adds Global Optoelectronics Industry 2Reportlinker Adds Global Optoelectronics Industry 3Reportlinker Adds Global Optoelectronics Industry 4Reportlinker Adds Global Optoelectronics Industry 5Reportlinker Adds Global Optoelectronics Industry 6Reportlinker Adds Global Optoelectronics Industry 7Reportlinker Adds Global Optoelectronics Industry 8Reportlinker Adds Global Optoelectronics Industry 9Reportlinker Adds Global Optoelectronics Industry 10Reportlinker Adds Global Optoelectronics Industry 11Reportlinker Adds Global Optoelectronics Industry 12Reportlinker Adds Global Optoelectronics Industry 13Reportlinker Adds Global Optoelectronics Industry 14Reportlinker Adds Global Optoelectronics Industry 15Reportlinker Adds Global Optoelectronics Industry 16Reportlinker Adds Global Optoelectronics Industry 17Reportlinker Adds Global Optoelectronics Industry 18Reportlinker Adds Global Optoelectronics Industry 19Reportlinker Adds Global Optoelectronics Industry 20Reportlinker Adds Global Optoelectronics Industry 21Reportlinker Adds Global Optoelectronics Industry 22Reportlinker Adds Global Optoelectronics Industry 23Reportlinker Adds Global Optoelectronics Industry 24Reportlinker Adds Global Optoelectronics Industry 25Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting 2
(Date:7/30/2015)... ... ... As more hospitals across the country see the value in developing their ... of growing competition, it is more important than ever to market a hospital’s ... at Wound Care Advantage has found that while many hospitals already have ...
(Date:7/30/2015)... ... ... OSF Healthcare System has been recognized as one of the nation’s ... & Health Networks. This marks the fourth consecutive year for this achievement by the ... Third Order of St. Francis . , Health data security and patient engagement are ...
(Date:7/30/2015)... ... ... between a healthy head of hair and a feeling of confidence is a powerful one ... have a devastating impact on the daily life of a person. From increased anxiety ... hair loss are not to be taken lightly. , The skilled staff at Parsa Mohebi ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has ... go. With no water needed, the refreshing berry-flavored tablets are the perfect travel ... the natural ingredients that may help with body detoxification, protection and hydration,” said ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
... eye cancer is greater among kidney transplant patients and ... public, which suggests the disease is associated with immune ... of New South Wales in Sydney and colleagues compared ... general population with that of kidney transplant patients, who ...
... apo A-I ratio is not a better predictor of ... include total cholesterol and HDL-C, according to a study ... risk-prediction instruments and guidelines for coronary heart disease (CHD) ... total cholesterol, or both for CHD risk assessment. But ...
... parents informational handouts can improve their understanding of the ... according to a recent study conducted by researchers from ... School of Medicine in New Haven, CT. , Like ... about the increasing radiation exposure to children caused by ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... tell us when middle-aged spread is getting out of hand. ... the ready. New research shows that adding several inches to ... rangemarkedly increases the risk of unhealthy plaque build-up in the ... , The research, conducted at the University of Texas Southwestern ...
... indicates that the loss of two types of brain ... of symptoms associated with Parkinson,s disease. , The evidence, ... loss of both norepinephrine and dopamine neurons and the ... was originally thought that the loss of only dopamine ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Pot bellies linked to early signs of cardiovascular disease 2Health News:Pot bellies linked to early signs of cardiovascular disease 3Health News:Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinson's symptoms 2
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
... utilizes a new, improved format that requires only ... detection. The testing device employs innovative lateral flow ... already been applied to the testing strip. Workflow ... results shown by the appearance of an easy-to-read ...
Medicine Products: